share_log

Virios Therapeutics Analyst Ratings

Benzinga Analyst Ratings ·  Sep 20, 2022 06:24
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/20/2022 HC Wainwright & Co. Downgrades Buy → Neutral
12/15/2021 500% HC Wainwright & Co. → $12 Initiates Coverage On → Buy

Virios Therapeutics Questions & Answers

What is the target price for Virios Therapeutics (VIRI)?

The latest price target for Virios Therapeutics (NASDAQ: VIRI) was reported by HC Wainwright & Co. on September 20, 2022. The analyst firm set a price target for $0.00 expecting VIRI to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Virios Therapeutics (VIRI)?

The latest analyst rating for Virios Therapeutics (NASDAQ: VIRI) was provided by HC Wainwright & Co., and Virios Therapeutics downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for Virios Therapeutics (VIRI)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Virios Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Virios Therapeutics was filed on September 20, 2022 so you should expect the next rating to be made available sometime around September 20, 2023.

Is the Analyst Rating Virios Therapeutics (VIRI) correct?

While ratings are subjective and will change, the latest Virios Therapeutics (VIRI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Virios Therapeutics (VIRI) is trading at is $2.00, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment